Nintedanib reverses this resistance through dual mechanisms: it directly inhibits FGFR and PDGFR activity, and reduces the availability of RTK ligands (e.g., FGF, PDGF) in the tumor microenvironment (TME) via its anti‐angiogenic effect. This evidence concerns the gene PDGFRB and neoplasm.